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Abstract
Aims Maturity Onset Diabetes of the Young (MODY) is a monogenic form of diabetes with autosomal dominant inheritance 
pattern. The diagnosis of MODY and its subtypes is based on genetic testing. Our aim was investigating MODY by means 
of next-generation sequencing in the Tunisian population.
Methods We performed a targeted sequencing of 27 genes known to cause monogenic diabetes in 11 phenotypically sus-
pected Tunisian patients. We retained genetic variants passing filters of frequency in public databases as well as their probable 
effects on protein structures and functions evaluated by bioinformatics prediction tools.
Results Five heterozygous variants were found in four patients. They include two mutations in HNF1A and GCK that are the 
causative genes of the two most prevalent MODY subtypes described in the literature. Other possible mutations, including 
novel frameshift and splice-site variants were identified in ABCC8 gene.
Conclusions Our study is the first to investigate the clinical application of targeted next-generation sequencing for the diag-
nosis of MODY in Africa. The combination of this approach with a filtering/prioritization strategy made a step towards the 
identification of MODY mutations in the Tunisian population.
Keywords MODY · Genetic testing · Next-generation sequencing · Targeted gene sequencing
Introduction
Maturity Onset Diabetes of the Young (MODY) is a mono-
genic form of non-insulin-dependent diabetes that classically 
presents in a lean individual with non ketotic hyperglycae-
mia and an autosomal dominant inheritance pattern. Most 
cases are diagnosed before the age of 25 [1].
MODY (OMIM Entry: #606391) has been recognized 
as a clinically and genetically heterogeneous condition. To 
date, more than 1000 variants were identified in at least 14 
genes which define MODY subtypes [2–4]. Some of these 
genes are involved in pancreas and beta-cell development, 
while others play crucial roles in the various steps of insulin 
secretion, such as glucose sensing, and its metabolism in the 
beta cells [5].
Prevalence of MODY is difficult to estimate due to the 
overlapping of its clinical features with those of type 1 and 
type 2 diabetes, and therefore most cases are missed [6]. 
Some studies have reported that MODY accounts for 1–5% 
of the young-onset diabetes population [7–10].
Classification of MODY subtypes is based on underly-
ing the genetic variation on the candidate genes. The genes 
encoding the hepatic transcription factors HNF1A and 
HNF4A, along with the gene encoding the glucokinase, 
account for approximately 95% of all identified MODY 
cases [11].
Diagnosing MODY in young patients with diabetes 
is crucial to provide accurate counselling about the pre-
dicted clinical outcomes. Moreover, it allows subsequent 
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identification of affected family members, and most impor-
tantly, appropriate management [12]. Indeed, misdiagnosis 
of MODY as type 1 diabetes (T1D) leads to inappropriate 
insulin therapy. For instance, in the case of HNF1A MODY, 
sulphonylureas, an inexpensive oral anti-diabetes medica-
tion, has shown its efficiency as a first-line treatment [13]. 
GCK MODY does not require medications as it leads to a 
mild fasting hyperglycaemia that is not associated with sig-
nificant complications [14].
Traditional genetic testing of MODY consists of Sanger 
sequencing of the three most common MODY genes includ-
ing 31 exons. However, this technique is expensive and 
time-consuming. The cost of sequencing the other candidate 
genes precludes further genetic testing, thus increasing the 
missing MODY cases [15].
The advent of high-throughput Next-Generation Sequenc-
ing (NGS) technologies has launched a revolution in screen-
ing strategies enabling simultaneous analysis of a panel of 
genes at a lower cost compared with testing few genes by 
Sanger sequencing. Indeed, NGS panels for MODY investi-
gation studies were carried out in European, American and 
Asian populations [16–19].
In Tunisia, three studies screened for genetic variants in 
some known MODY genes by classical methods. The first 
study identified a variant in HNF4A gene defining a MODY 
1 subtype in only one patient, while 11 patients were found 
negative for variations in GCK, HNF1A, HNF4A, HNF1B, 
INS, IPF1 and NEUROD1 genes [20]. Six among these 11 
patients were also negative for variations in PAX4 gene [21]. 
The last study identified only two GCK and HNF4A variants 
in three among 23 suspected Tunisian MODY patients [22]. 
These studies suggested that the most common genes known 
for MODY do not explain the majority of cases in Tunisians.
In this study, we investigate the genetic aetiology of 11 
suspected Tunisian MODY patients by means of targeted 
NGS of a genes panel.
Materials and methods
Study subjects
This study was conducted according to the Declaration of 
Helsinki. It was approved by Pasteur Institute of Tunis ethics 
committee (Reference: 2016/19/I/LR11IPT05) and a written 
informed consent was obtained from the participants.
A total of 44 patients were recruited from the National 
Institute of Nutrition of Tunis based on the following 
criteria:
• Young onset of diabetes: age at diagnosis < 40 years old.
• Positive family history of diabetes in at least two genera-
tions.
• Absence of ketosis
Autoantibodies to Glutamic Acid Decarboxylase (GAD), 
Islet Antigen 2 (IA2) as well as Islet Cell Antibodies (ICA) 
were analysed in the immunology laboratory of Institut Pas-
teur of Tunis as they are the biological markers of type 1 
diabetes patients [23].
These criteria were used at the recruitment for primary 
classification aiming at excluding obvious type 1 and type 
2 diabetes patients to increase the likelihood of MODY 
discovery.
Clinical characteristics, including demographic informa-
tion, anthropometric measures, and diabetes history were 
collected during a survey prior to blood sample.
Metabolic parameters including fasting plasma glucose 
(FPG), glycated haemoglobin (HBA1c), cholesterol, high-
density lipoproteins (HDL), low-density lipoproteins (LDL), 
triglycerides (TG), creatinine and C-reactive protein (CRP) 
were measured in the biochemistry laboratory of Pasteur 
Institute of Tunis.
Among the 44 patients, almost full records were available 
for 11 who were selected for genetic testing with a gene 
panel-based next-generation sequencing approach. The other 
33 patients were not included in the present study because 
of the lack of several additional clinical information (such 
as presence/absence of diabetes complications: micro/macro 
albuminuria, diabetic nephropathy, glycosuria, retinopathy 
as well as detailed treatment history) that does not allow us 
to comment on any genotype–phenotype correlation.
Targeted next‑generation sequencing
Genomic DNA was isolated from the blood using the Flexi-
gen DNA kit (QIAGEN). DNA quality was assessed using 
nanodrop spectrophotometer (Thermofisher scientific) and 
Qubit 3.0 (Life technologies).
Targeted capture and massive parallel sequencing of 
27 genes reported to cause monogenic forms of diabetes 
were performed at CSS-Mendel Institute, Rome (Italy) as 
we recently described [24]. The list of genes is provided in 
Online Resource 1 (Table S1).
Bioinformatics analysis
The raw FASTQ files, generated by MiSeq reporter software 
were aligned to the hg19 reference human genome. Then, 
variants were called for each individual sample in VCF files.
Coverage statistics were computed using Varaft 2.06 
software [25]. Genetic variants were filtered to include only 
those with > 20× read depth and quality mapping score ≥ 30.
Annotation of variants was carried out with Annovar 
database [26]. The likely pathogenicity of annotated genetic 
variants was evaluated according to the following pipeline:
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• Synonymous genetic variants were filtered out, keeping 
only nonsense, missense, frameshift insertions/deletions 
and splice-site variants, as they are more likely to have 
functional effect.
• Genetic variants with minor allele frequency (MAF) 
> 1% in gnomAD database (http://gnoma d.broad insti 
tute.org/) were excluded.
• The pathogenicity of the missense variants was assessed 
in silico by 13 prediction tools using a pathogenicity 
score as previously reported [24].
• The pathogenicity of splice-site variants was predicted 
in silico by the Human Splicing Finder [27] and SPiCE 
tools [28].
We searched bioinformatic databases: Pubmed (https ://
www.ncbi.nlm.nih.gov/pubme d), Clinvar (https ://www.ncbi.
nlm.nih.gov/clinv ar) and LOVD [29] for genetic variants 
surviving the filtering/prioritization pipeline to determine if 
they were previously reported and if so, their relevant studies 
and ontologies.
The following genetic variants were retained:
• Missense variants with a total predicted pathogenicity 
score > 7.
• Nonsense and frameshift variations being by their intrin-
sic nature considered as pathogenic or likely pathogenic.
• Variants reported to alter splice sites by the Human Splic-
ing Finder and SPiCE tools.
The retained variants were finally checked using the 
Mutalyzer program [30].
Sanger sequencing
Sanger sequencing was performed to confirm the likely path-
ogenic predicted variants in the probands, and to check the 
familial segregation when possible. In brief, genetic variants 
containing exons were amplified from DNA samples by pol-
ymerase chain reaction (PCR) using oligonucleotide primers 
designed by Primer3 software (available upon request). The 
resulting amplicons were sequenced on automated ABI3500 
(Applied Biosystems, CA, USA) using the ABI prism Big 
Dye terminator v3.1 cycle sequencing kit. Sequence analysis 
was performed using BioEdit software [31].
Results
The clinical characteristics of the 11 Tunisian study partici-
pants are summarized in Table 1.
The exons of 27 genes were enriched with TruSeq Cus-
tom amplicon low-input library preparation kit and were 
sequenced with Illumina MiSeq technology. The average 
read depth across the targeted regions was 1422× with 
94.2% covered > 20×.
The filtering/prioritization pipeline resulted in the iden-
tification of three non-synonymous variants, one frameshift 
deletion and one splice-site variant in four patients (Fig. 1). 
They include two novel and three previously reported muta-
tions (Table 2). Binary bioinformatic pathogenicity scores 
are provided in Online Resource 1 (Table S2).
The two novel variants were identified in the ABCC8 
gene and were carried by the patient MODY-TUN-P01. 
The first is a frameshift deletion resulting in the loss of 
approximately 50% of the amino acids of the ABCC8 pro-
tein: c.2376delC/p.Phe793Serfs*71. The second is a splice-
site variant: c.4608 + 4A > G, which alters the donor splice 
site near the exon 38 according to the Human Splice Finder 
and SPiCE tools. The patient developed a relatively late 
clinical manifestation of diabetes (at age of 32 years old) 
with a dramatic increase in glycaemia (FPG = 22.7 mmol/l 
and HBA1c > 7%) and a persistent polyuria and polydipsia. 
There are no signs of ketosis or positive pancreatic autoan-
tibodies. Two months of insulin therapy resulted in FPG 
decline to 7.06 mmol/l. Sanger sequencing confirmed the 
presence of the two heterozygous variants in the proband, 
the presence of only the frameshift deletion in the father 
having high TG, and the splice-site variant in the mother 
with type 2 diabetes mellitus.
The patient MODY-TUN-P15 carried a heterozygous 
missense variant in the ABCC8 gene: c.4606G > A/p.Ala-
1536Thr. This genetic variant was predicted as pathogenic 
by 10 prediction tools and it is very rare according to gno-
mAD (MAF = 8.12 × 10−6). It has an identifier in dbsnp data-
base but without any clinical information. This patient has 
been diagnosed with fasting hyperglycaemia (8.25 mmol/l) 
at 10 years old. He had strong diabetes family history and 
has taken an oral anti-diabetes drug (OAD) for 25 years. 
The clinical follow-up demonstrated a progressive glycosu-
ria, and the biochemical analysis upon enrolment revealed 
high TG and cholesterol levels as well as a persistent fast-
ing hyperglycaemia. Pancreatic antibodies were negative 
and endogenous insulin secretion was suggested by a normal 
C-peptide level (1.4 ng/ml). Sanger sequencing confirmed 
the existence of the variant in the patient, but no family 
members were available to check its familial segregation.
In patient MODY-TUN-P12, we identified a missense 
variant in HNF1A gene: c.710A > G/p.Asn237Ser, that 
was attributed a pathogenic effect by 12 prediction tools. 
The patient was diagnosed with fasting hyperglycaemia 
(7.38 mmol/l), polyuria and polydipsia at 11 years old. 
He took both metformin and sulfonylurea, resulting in a 
decrease of FPG that has been then not stabilized within 
the range of 7–13 mmol/l due to an irregular uptake of the 
OAD according to the clinical follow-up. This patient has no 
signs of pancreatic antibodies. Biochemical analyses showed 
 Acta Diabetologica
1 3
Ta
bl
e 
1 
 C
lin
ica
l c
ha
ra
cte
ris
tic
s o
f t
he
 11
 su
sp
ec
ted
 T
un
isi
an
 M
OD
Y 
pa
tie
nt
s
M
icr
oa
lb
um
in
ur
ia 
wa
s d
iag
no
se
d 
if 
ur
in
ar
y 
alb
um
in
 >
 30
 m
g/
24
 h
, n
or
m
al 
tri
gl
yc
er
id
es
 le
ve
ls:
 0
.57
–1
.71
 m
m
ol
/l,
 n
or
m
al 
cr
ea
tin
in
e l
ev
els
: 6
0–
12
0 
µm
ol
/l,
 n
or
m
al 
C-
pe
pt
id
e l
ev
els
: 1
.1–
3.5
 n
g/
m
l, 
no
rm
al 
HD
L 
lev
els
 >
 1 
m
m
ol
/l,
 no
rm
al 
ch
ol
es
ter
ol
 le
ve
ls:
 4.
1–
6.2
 m
m
ol
/l
BM
I B
od
y 
M
as
s I
nd
ex
, F
 fe
m
ale
, F
PG
 fa
sti
ng
 p
las
m
a 
gl
uc
os
e, 
H
BA
1c
 g
lyc
ate
d 
ha
em
og
lo
bi
n, 
H
D
L 
hi
gh
-d
en
sit
y 
lip
op
ro
tei
ns
, M
 m
ale
, O
AD
 o
ra
l a
nt
id
iab
ete
s d
ru
gs
, T
G
 tr
ig
lyc
er
id
es
, N
A 
no
t 
av
ail
ab
le
a  T
hr
ee
 ne
ga
tiv
e d
en
ot
es
 ne
ga
tiv
e r
es
ul
ts 
fo
r t
he
 th
re
e p
an
cr
ea
tic
 an
tib
od
ies
Pa
tie
nt
Se
x
Di
sc
ov
er
y c
ir-
cu
m
sta
nc
es
 an
d 
sy
m
pt
om
s
Ag
e a
t 
di
ag
no
sis
 
(y
ea
rs)
Ag
e a
t 
su
rv
ey
 
(y
ea
rs)
Pa
re
nt
s 
wi
th
 
di
ab
ete
s
Tr
ea
tm
en
t
Ti
m
e t
o 
in
su
lin
BM
I (
kg
/m
2 )
Hb
A1
C%
 
(m
m
ol
/
m
ol
)
Pa
nc
re
ati
c 
an
tib
od
ies
C 
pe
p-
tid
e (
ng
/
m
l)
Ot
he
r c
lin
ica
l 
fea
tu
re
s
M
OD
Y-
TU
N-
P0
1
M
Po
ly
ur
ia,
 po
ly
di
ps
ia
FP
G 
= 
22
.7 
m
m
ol
/l
32
33
1
In
su
lin
0
25
.26
7.9
 (6
3)
Th
re
e 
 ne
ga
tiv
ea
NA
FP
G 
= 
7.0
6 m
m
ol
/l
M
OD
Y-
TU
N-
P0
3
F
Th
ird
 pr
eg
na
nc
y
FP
G 
= 
12
.48
 m
m
ol
/l
38
39
2
In
su
lin
1 m
on
th
22
.32
6.6
 (4
9)
Th
re
e n
eg
a-
tiv
e
0.8
Re
tin
op
ath
y
Lo
w 
cr
ea
tin
in
e l
ev
els
Hi
gh
 T
G
M
OD
Y-
TU
N-
P0
8
M
Po
ly
ur
ia,
 po
ly
di
ps
ia
W
eig
ht
 lo
ss
FP
G 
= 
9.8
 m
m
ol
/l
25
28
1
In
su
lin
 +
 O
AD
1 y
ea
r
21
.97
7.4
 (5
7)
Th
re
e n
eg
a-
tiv
e
0.4
Lo
w 
TG
M
OD
Y-
TU
N-
P1
2
M
Po
ly
ur
ia,
 po
ly
di
ps
ia
FP
G 
= 
7.3
8 m
m
ol
/l
11
18
1
OA
D
No
n s
tab
le 
gl
yc
ae
m
ia 
up
on
 an
 
irr
eg
ul
ar
 
up
tak
e o
f 
OA
D
No
24
.88
8.5
 (6
9)
Th
re
e n
eg
a-
tiv
e
1.5
Lo
w 
HD
L 
lev
els
Lo
w 
ch
ol
es
ter
ol
 
lev
els
M
icr
oa
lb
um
in
ur
ia
M
OD
Y-
TU
N-
P1
5
M
Fo
rtu
ito
us
FP
G 
= 
8.2
5 m
m
ol
/l
10
35
2
OA
D
No
25
.46
9.4
 (7
9)
Th
re
e n
eg
a-
tiv
e
1.4
Gl
yc
os
ur
ia
Hi
gh
 T
G
Hi
gh
 ch
ol
es
ter
ol
FP
G 
= 
12
.42
 m
m
ol
/l
M
OD
Y-
TU
N-
P2
3
F
Po
ly
ur
ia,
 po
ly
di
ps
ia
FP
G 
= 
20
.26
 m
m
ol
/l
19
22
1
OA
D
Hy
pe
rte
ns
io
n 
tre
atm
en
t
No
31
7.0
 (5
3)
Th
re
e n
eg
a-
tiv
e
2
Ch
ol
es
tas
is
FP
G 
= 
7.9
4 m
m
ol
/l
M
icr
oa
lb
um
in
ur
ia
M
OD
Y-
TU
N-
P2
5
F
Pr
eg
na
nc
y
FP
G 
= 
16
.5 
m
m
ol
/l
25
29
2
OA
D 
fo
r 
2 y
ea
rs
In
su
lin
3 y
ea
rs
23
.7
7.1
 (5
4)
Th
re
e n
eg
a-
tiv
e
1.4
6
Lo
w 
TG
M
OD
Y-
TU
N-
P3
0
F
Po
ly
ur
ia,
 po
ly
di
ps
ia
FP
G 
= 
19
.25
 m
m
ol
/l
24
25
1
OA
D
No
24
.72
6.3
 (4
5)
Th
re
e n
eg
a-
tiv
e
4.1
Gl
yc
os
ur
ia
M
OD
Y-
TU
N-
P3
9
F
Po
ly
ur
ia,
 po
ly
di
ps
ia
FP
G 
= 
17
 m
m
ol
/l
25
28
0
In
su
lin
2 y
ea
rs
25
.2
5.8
 (4
0)
Th
re
e n
eg
a-
tiv
e
0.4
De
ve
lo
pm
en
t d
ela
y
M
icr
oa
lb
um
in
ur
ia 
FP
G 
= 
5.6
5 m
m
ol
/l
M
OD
Y-
TU
N-
P4
2
M
Fo
rtu
ito
us
FP
G 
= 
10
.11
 m
m
ol
/l
26
26
2
OA
D
No
23
6.6
 (4
9)
Th
re
e n
eg
a-
tiv
e
1.8
Lo
w 
HD
L
FP
G 
= 
4.8
6 m
m
ol
/l
M
OD
Y-
TU
N-
P4
4
M
Fo
rtu
ito
us
HB
A1
c =
 6.
9%
9
9
1
No
 tr
ea
tm
en
t
No
16
.15
5.8
 (4
0)
Th
re
e n
eg
a-
tiv
e
NA
–
Acta Diabetologica 
1 3
Fig. 1  Pedigrees of the four patient’s families carrying the filtered 
genetic variants. The arrow indicates the proband, double lines indi-
cate consanguineous matings, white squares and circles indicate 
healthy males and females, respectively, black squares and circles 
indicate males and females with diabetes. N/M denotes mutation, 
while N/N denotes no mutation. Below the genotype are: age at 
recruitment, age at diabetes diagnosis and specific anti-hyperglycae-
mia treatment
Table 2  List of the filtered genetic variants identified in the suspected Tunisian MODY patients
gnomAD the genome aggregation database (http://gnoma d.broad insti tute.org/), dbSNP single nucleotide polymorphism database
Patient Gene Refseq Genetic variant Consequence dbSNP gnomAD Fre-
quency
Patho-
genicity 
score
Reference
MODY-TUN-P01 ABCC8 NM_000352.4 c.2376delC p.Phe793Serfs*71 – – – Present study
c.4608 + 4A > G Splice-site substi-
tution
– – – Present study
MODY-TUN-P12 HNF1A NM_000545.6 c.710A > G p.Asn237Ser – – 12 LOVD [29]
MODY-TUN-P15 ABCC8 NM_000352.4 c.4606G > A p.Ala1536Thr rs772332005 8.12e−06 10 gnomAD
MODY-TUN-P44 GCK NM_000162.3 c.571C > T p.Arg191Trp – 8.13e−06 12 LOVD [29]
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C-peptide value in the reference range (1.5 ng/ml). Sanger 
sequencing revealed the presence of the heterozygous 
genetic variant in both the proband and his twin sister who 
developed diabetes at approximately the same age. Parental 
samples were not available to check familial segregation.
The patient MODY-TUN-P44 was diagnosed with 
mild hyperglycaemia at the age of 9. NGS results analysis 
showed that he carried a missense variant in GCK gene: 
c.571C > T/p.Arg191Trp. This genetic variant was predicted 
as pathogenic by 12 bioinformatic tools and it is very rare 
according to gnomAD (MAF = 8.13 × 10−6). This patient 
is a member of a family with diabetes history across three 
generations in both sides. Sanger sequencing revealed the 
presence of the genetic variant in the proband and only his 
father having type 2 diabetes mellitus, which points out an 
autosomal dominant inheritance pattern.
Discussion
In the current study, we performed the targeted sequenc-
ing of 27 genes reported to cause monogenic diabetes in 
suspected Tunisian MODY patients in order to detect the 
causative genetic variants. To our knowledge, this study is 
the first of this type to investigate the clinical application of 
NGS in the diagnosis of MODY in Africa.
The high throughput of sequencing technologies results in 
increased amount of genetic variants whose causative role in 
the investigated disease is questionable [32]. To surpass this 
problem, the likely pathogenicity of the observed genetic 
variants was evaluated by a combined filtering/prioritiza-
tion strategy according to reads depth and quality, allele fre-
quency, predicted functional impact by bioinformatic predic-
tion tools known for their high classification records [24, 
33], clinical features of patients as well as with extensive 
literature search for reported clinical and functional studies.
We identified 5 likely pathogenic mutations in 4 among 
11 patients. They include two variants in the genes defining 
the two most prevalent MODY subtypes, which are HNF1A 
and GCK accounting for roughly 70% of cases [34].
Variants in HNF1A gene are the most common causes of 
MODY, responsible for 52% of monogenic diabetes in the 
United Kingdom [6]. Moreover, they demonstrate high pen-
etrance, in which almost 63% of mutation carriers develop 
diabetes before 25 years old [35]. Our assay results analy-
sis revealed that both MODY-TUN-P12 and his twin sister 
carried a missense variant located in the highly conserved 
 POUH domain of HNF1A, which initiates the interaction of 
the transcription factor protein with target genes expressed 
in the pancreas and the liver, and involved in glucose trans-
port and metabolism. This variant was previously found in 
two suspected MODY females from England aged 12 and 
15, respectively, by K. Colclough in Exeter hospital (United 
Kingdom) [29]. All these arguments may suggest the pos-
sible causative effect of the identified variant within the 
HNF1A gene.
The GCK variant was identified in a 9-year-old boy diag-
nosed with slightly elevated HBA1c. According to LOVD 
database, it was previously reported in seven persons with 
diabetes of Brazilian and Italian ethnic origin with probable 
pathogenic effect towards MODY subtype [29]. The affected 
amino acid is localized in a functional domain that is cru-
cial in the conformational change of the glucokinase to its 
active state for the catalysis of the glucose phosphorylation 
reaction [36].
The other three retained variants in our study were 
located in the ABCC8 gene which encodes the sulphonyluria 
receptor 1 (SUR1) subunits of the ATP-sensitive potassium 
channel in the pancreatic beta cells. This channel links the 
insulin secretion by regulating the potassium ion flow across 
the beta cell membrane. The first is a novel splice-site vari-
ant in ABCC8 gene: c.4608 + 4A > G, which was identified 
in the patient MODY-TUN-P01 as well as in his diabetic 
mother. Both “Human Splicing Finder” and “SPiCE” tools 
predicted splicing alteration through the possible break of 
the donor splice site located at 5′ of intron 38. Therefore, the 
A to G transition at four bp positions downstream of exon 
38 may decrease the recognition of the intron 38 wild type 
donor site, which may lead to the activation of a cryptic 
splice site. We have analysed the ± 100 bp region on each 
side of the exon–intron boundary using “Human Splicing 
Finder” to check the presence of potential splice sites. This 
shows the possibility of activation of a cryptic splice site at 
position 52 in the exon 38, which causes the loss of 12 bp of 
this exon. Another possibility is the activation of a cryptic 
splice site in intron 38 at position c.4608 + 21, which may 
insert 20 bp of intronic sequence between exons 38 and 39. 
The aberrant splicing is predicted to result in a truncated 
protein due to a premature termination at codon 1550. This 
would result in the obtaining of an ABCC8 protein with 1549 
among the original 1581 amino acids, including 13 different 
ones. Having said all this, we do acknowledge that functional 
experiments are needed to validate the real effect of this vari-
ant on the messenger RNA of ABCC8 gene and to eventually 
address its role in concurring to cause hyperglycaemia.
In addition, this patient carried a novel frameshift dele-
tion, c.2376delC/p.Phe793Serfs*71, most probably result-
ing in a loss of function of the ABCC8 protein. This variant 
was also present in the non-diabetic father, which may rule 
out a probable effect on hyperglycaemia. Taken all together, 
while waiting for further and deeper studies, no firm conclu-
sions can be drawn on the role of the two above-mentioned 
ABCC8 variants on hyperglycaemia.
The third ABCC8 variant occurred in the patient MODY-
TUN-P15 diagnosed with diabetes for 25  years since 
10 years old, and who has a brother who died at 1 year old 
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with neonatal hyperglycaemia. Missense variants in this 
gene were implicated in variable clinical phenotypes with 
glucose intolerance, mild hyperglycaemia or insulin-requir-
ing diabetes from a young age (neonatal diabetes due to 
recessive mutations) to adulthood (MODY due to heterozy-
gote mutations) even within the same pedigree [37–40].
Our study contributed to better understand the pathophys-
iology of diabetes in patients with genetic characterisation. 
In fact, the identification of the HNF1A mutation confirmed 
the sulphonylurea treatment for the patient MODY-TUN-
P12, who had unstable glycaemia upon an irregular uptake 
of his medications. For the patient MODY-TUN-P15, OAD 
treatment as a monotherapy provided good glycaemia con-
trol over approximately 25 years, which demonstrated the 
good response to OAD for this ABCC8-MODY patient. 
However, the recent combination of hyperglycaemia, high 
TG and cholesterol levels with glycosuria should be noted 
as indicators towards the addition of insulin therapy. Indeed, 
ABCC8 mutations were described in cases who success-
fully switched from insulin to sulfonylurea, as well as in 
insulin-requiring diabetic patients [38, 39]. Regarding the 
patient MODY-TUN-P01, he was maintained under insu-
lin treatment, as deeper studies are required for the valida-
tion of the effect of ABCC8 genetic variant. Finally, for the 
patient MODY-TUN-P44, recently diagnosed with diabetes, 
the identification of the causative mutation in GCK gene 
denoted a MODY 2 subtype, which requires only a diet for 
a better management of the hyperglycaemia. Non-carrying 
mutation family members have benefited from a genetic 
counselling to ensure them that they did not have the risk 
factor for hyperglycaemia.
Interestingly, there is an early onset of retinopathy or 
microalbuminuria in 4 of the 11 suspected MODY patients. 
This observation can be explained for the patients MODY-
TUN-003, MODY-TUN-023 and MODY-TUN-039 by the 
late diagnosis of diabetes. For the patient MODY-TUN-P12, 
the irregular treatment with OAD led to hyperglycaemia dur-
ing 7 years. This may cause vascular complications, which 
are known to be associated with significantly higher rates of 
microalbuminuria [41].
Genetic cause was not identified in 7 of the 11 selected 
patients. This result can be due to a certain clinical over-
lap between MODY and other forms of diabetes in these 
patients. Another explanation is that the cause of diabetes 
may be in currently unknown MODY genes. In addition, we 
do acknowledge that the exclusion of patients with hyper-
ketonaemia, a clinical characteristic of T1D, might have 
excluded patients with MODY 3 who quite rarely may pre-
sent as such condition [42, 43].
Targeted NGS assays to identify mutations causing 
MODY have been developed in previous studies using 
various capture kits. The first study, carried out by Ellard 
et al. on 2013, investigated 33 suspected MODY patients 
by massive parallel sequencing of 29 genes implicated in 
neonatal diabetes, MODY, maternally inherited diabetes 
and deafness (MIDD) or familial partial lipodystrophy [16]. 
Mutations were identified in five patients, including two 
mutations in the m.3243 region of the mitochondrial genome 
known to cause MIDD. This result denotes the overlapping 
criteria for the distinction of MODY from other forms of 
diabetes.
This first assay was followed by some studies testing for 
monogenic diabetes including MODY [17, 19, 24, 44, 45]. 
Recruitment criteria were relatively specific in each study. 
For example, the age at diagnosis threshold varied between 
30 and 45 years in studies realized in Poland and Asian pop-
ulations, respectively [44, 45]. Aranburu et al. investigated 
suspected American MODY patients with either linear his-
tory of diabetes or the absence of the type 1 diabetes-related 
pancreatic autoantibodies [19]. All these parameters were 
included in our recruitment strategy to evaluate the combina-
tion between clinical investigation and targeted NGS in the 
identification of MODY cases.
Conclusion
The present study reported the results of genetic investiga-
tion of Tunisian suspected MODY patients. This population 
is characterized by a particular structure, i.e. a very diverse 
genetic background and a high rate of consanguinity that 
influence its genetic make-up. Consequently, genes respon-
sible for MODY might be different from those reported in 
other Caucasian populations. Indeed, our study shows that 
the most frequently reported genes are not apparently the 
major genes involved in MODY in our population. In this 
context, exome sequencing presents an alternative to look for 
genetic variants in not currently reported genes.
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